In today’s briefing:
- Initial Thoughts on the KOSPI200 Rebalance in June 2022
- Emcure Pharmaceuticals Pre-IPO – Proforma Earnings Were Strong but It Faces a Host of Legal Issues
- Pre-IPO Biocytogen Pharmaceuticals – The Novel Development Model Offset the Pipeline’s Shortcomings
- Metropolis Healthcare Ltd – Q3FY22 Result Update
- Apollo Hospitals: In Line Quarter; Numbers Trend Pre-Covid Level
- Glenmark Pharmaceuticals: Launches, Margins Sustainability to Hold Key
Initial Thoughts on the KOSPI200 Rebalance in June 2022
- In this insight, we discuss the potential additions and deletions in the upcoming June 2022 KOSPI200 rebalance.
- These top 10potential inclusionsare down on average 4.4% YTD, outperforming KOSPI which is down 10.1% YTD.
- These top 10 potential exclusions are down on average 12.3% YTD, underperforming KOSPI which is down 10.1% YTD.
Emcure Pharmaceuticals Pre-IPO – Proforma Earnings Were Strong but It Faces a Host of Legal Issues
- Emcure Pharmaceuticals Limited is looking to raise around US$500m in its upcoming India IPO.
- EP is an Indian Pharmaceutical company engaged in the developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
- In this note, we talk about the various aspects of the deal.
Pre-IPO Biocytogen Pharmaceuticals – The Novel Development Model Offset the Pipeline’s Shortcomings
- The candidates in Biocytogen’s pipeline do not have advantages in development progress and also have to face fierce competition, so continuous large R&D investment in the future would be inevitable.
- However, the development model of Biocytogen is very novel and special, which could make it a rare target in the market if it is successfully listed.
- Therefore, the certainty of Biocytogen’s future growth is expected to improve gradually, and the mid- and long-term investment value would continue to increase due to the high moat.
Metropolis Healthcare Ltd – Q3FY22 Result Update
- Missed estimates, margin contraction with lower realisations.
Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.
Apollo Hospitals: In Line Quarter; Numbers Trend Pre-Covid Level
- Apollo is one of the leading integrated healthcare service provider with avenues like hospitals, pharmacies, primary care & diagnostic clinics
- Apollo reported in line results but it was skewed with hospitals lagging our expectations while pharmacies were a beat on our estimates
- Target Price and Valuation: We value Apollo at Rs 5480 based on SOTP valuation.
Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.
Glenmark Pharmaceuticals: Launches, Margins Sustainability to Hold Key
- Glenmark Pharmaceuticals for building a global generic, specialty and OTC business in therapy areas of dermatology, respiratory, oncology among others
- Glenmark Life Sciences for manufacturing and marketing API
- Innovation new company (ICHNOS) to focus on discovery and development of novel, firstinclass treatments
Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.
Before it’s here, it’s on Smartkarma
